Last Update 10 Jul 26
Fair value Increased 24%EMEIS: Strengthened Governance And Stabilized Finances Will Support Future Re rating
The analyst price target for emeis Société anonyme has increased from €13.28 to about €16.53, with analysts citing a more stabilized financial structure as a key reason for the reassessment.
What's in the News for emeis Société anonyme
- CEO Laurent Guillot is reshaping emeis Société anonyme’s organisational structure to support growth plans and care quality, with several senior appointments announced. [Source: Changes to emeis’ Governance]
- Jean-Marc Boursier is set to become Group Chief Operating Officer from 1 September 2026, taking responsibility for operations across all countries after previously overseeing finances, information systems, procurement performance and selected regions. [Source: Changes to emeis’ Governance]
- Julia Clavel has been appointed Group Chief Financial Officer from 1 October 2026, after joining emeis in November 2023 as Director of Strategy, Innovation and M&A and overseeing Poland, England and Ireland. [Source: Changes to emeis’ Governance; Executive Changes: CFO]
- Sylvie Brisson has been named Group EVP Human Resources and Maria de la Mota Group EVP Medical, reinforcing the senior leadership team around operations, HR and medical functions. [Source: Changes to emeis’ Governance]
- A Board meeting held on 23 June 2026 included an agenda item to consider the appointment of Olivier Dussopt as Chairman of the Board of Directors of emeis Société anonyme. [Source: Board Meeting]
Valuation Changes for emeis Société anonyme
- Fair Value was updated from €13.28 to about €16.53 per share, implying a higher reference point for emeis Société anonyme’s estimated worth.
- The Discount Rate moved from 9.76% to about 11.54%, indicating a higher required return being applied in the valuation work.
- Revenue Growth was adjusted from 4.03% to about 3.77%, reflecting slightly more conservative assumptions for future € revenue expansion.
- Net Profit Margin was revised from about 0.75% to about 0.47%, pointing to a lower share of € profit on each euro of revenue in the model.
- Future P/E was updated from about 58.11x to about 120.0x, indicating a much higher earnings multiple being used for emeis Société anonyme in the forward-looking valuation.
Catalysts
About emeis Société anonyme
emeis Société anonyme operates nursing homes and healthcare facilities across Europe, focusing on long term elderly care and clinical services.
What are the underlying business or industry changes driving this perspective?
- Progressive normalization of occupancy rates in key markets like France and Germany, supported by rising care needs as populations age, is expected to support mid single digit revenue growth and reinforce operating leverage, which in turn may lift EBITDA and EBIT over time.
- Greater pricing power as facilities move closer to mature occupancy levels and quality improvements are recognized by regulators and residents could enhance average daily rates and contribute to an expansion in EBITDA margin and net income.
- Demographic driven growth in demand for long term care capacity across Europe, combined with limited public sector supply, positions emeis to selectively ramp up existing sites and pursue new asset light developments, in line with a 4 to 5 percent annual revenue growth target and an ambition for double digit EBITDA CAGR.
- A structural shift to more disciplined, lower intensity development CapEx and partnership based real estate solutions may reduce capital intensity and interest costs, which could improve free cash flow generation and support deleveraging and earnings growth.
- A real estate partnership and disposal program that seeks to materially reduce net debt while preserving operational control of assets is intended to lower the leverage ratio, reduce financial expenses and potentially support equity value creation through higher net margins and earnings per share.
Assumptions
How have these above catalysts been quantified?
- Analysts are assuming emeis Société anonyme's revenue will grow by 3.8% annually over the next 3 years.
- Analysts assume that profit margins will increase from -5.1% today to 0.5% in 3 years time.
- Analysts expect earnings to reach €30.8 million (and earnings per share of €0.21) by about July 2029, up from -€298.4 million today. However, there is a considerable amount of disagreement amongst the analysts with the most bullish expecting €147.5 million in earnings, and the most bearish expecting €-34.6 million.
- In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 120.2x on those 2029 earnings, up from -7.6x today. This future PE is greater than the current PE for the GB Healthcare industry at 17.5x.
- Analysts expect the number of shares outstanding to remain consistent over the next 3 years.
- To value all of this in today's terms, we will use a discount rate of 11.54%, as per the Simply Wall St company report.
Risks
What could happen that would invalidate this narrative?
- Execution risk in the turnaround remains high. If emeis fails to sustain occupancy gains near 88% on the mature perimeter or if the expected recovery in underperforming units stalls, revenue growth could fall short of the guided 4 to 5 percent per year and operating leverage would weaken, putting pressure on EBITDA and net income.
- The business model is increasingly tied to real estate partnerships and large disposal programs. If property valuations in European healthcare real estate remain subdued for longer or fall further instead of recovering as management expects, this would limit upside from the new vehicle, slow deleveraging and keep interest expenses elevated, constraining earnings and free cash flow.
- Political and regulatory scrutiny of private elderly care remains intense, exemplified by recent media investigations in Ireland and ongoing debates in France about the legitimacy of the private sector. Tighter staffing rules, price caps or sanction driven admissions freezes would raise staff costs and limit pricing power, compressing margins and delaying the return to positive net income.
- The strategy assumes sustained demographic tailwinds and growing long term care needs across Europe. If public sector or nonprofit providers expand capacity faster than expected or governments shift funding away from private operators amid political pressure, emeis could lose share and face slower ramp up of new and existing facilities, dampening revenue growth and EBITDA expansion.
- The balance sheet, while improving, remains heavily leveraged even after disposals, with pro forma net debt of about EUR 3.8 billion and a leverage ratio still around 13 times. Any slowdown in EBITDA growth from the targeted 12 to 16 percent or a rise in funding costs could quickly erode coverage ratios, limiting strategic flexibility and weighing on net income and equity value.
Valuation
How have all the factors above been brought together to estimate a fair value?
- The analysts have a consensus price target of €16.53 for emeis Société anonyme based on their expectations of its future earnings growth, profit margins and other risk factors.
- In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be €6.6 billion, earnings will come to €30.8 million, and it would be trading on a PE ratio of 120.2x, assuming you use a discount rate of 11.5%.
- Given the current share price of €14.11, the analyst price target of €16.53 is 14.7% higher.
- We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.
Have other thoughts on emeis Société anonyme?
Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.
Create NarrativeHow well do narratives help inform your perspective?
Comments
0 commentsDisclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.